Home > Insider Trading > Filing (0001104659-20-010940)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1477845	Annovis Bio Inc.	ANVS	Pharmaceutical Preparations (2834)	262540421

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1733680	Claudine Bruck	C/O Annovis Bio, Inc. 1055 Westlakes Drive, Suite 300 Berwyn PA 19312		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-01-31	800	$6.00	800	No	4	P	Direct
Common Stock	Acquisiton	2020-01-31	3,969	$0.00	4,769	No	4	C	Direct
Common Stock	Acquisiton	2020-01-31	1,117	$4.80	5,886	No	4	C	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	C	Direct
No	4	C	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2020-01-31	5,556	$0.00	3,969	$0.00
Common Stock	Convertible Note	Disposition	2020-01-31	1,117	$4.80	1,117	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis").
Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price).